Interference From High-Dose Biotin Intake in Immunoassays for Potentially Time-Critical Analytes
by Roche

Evaluation of a Countermeasure for Worst-Case Scenarios

Ingo Mrosewski, MD; Matthias Urbank; Thomas Stauch, PhD; Rafael Switkowski, MD

Context.—Immunoassays using the interaction between streptavidin and biotin are used for clinical chemical analytes on platforms by many different manufacturers. The design can be susceptible to interference from high-dose biotin intake in patients, which remains an often-overlooked confounder despite recently increased awareness.

Objective.—To evaluate an easily implementable method of in vitro biotin depletion for the removal of biotin interference in immunoassays for potentially time-critical analytes.

Design.—A biotin stock solution was made and deidentified patient samples were spiked to reach a biotin concentration of $1.126 \times 10^6$ pg/mL, the maximum reported biotin concentration 1 to 2 hours after a single oral dose of 300 mg biotin. Then, the resulting interference in Elecsys immunoassays for cortisol, cyclosporine A, tacrolimus, digoxin, thyroid-stimulating hormone, free triiodothyronine, free thyroxine, C-peptide, insulin, N-terminal pro-B-type natriuretic peptide, troponin T high sensitive, human immunodeficiency virus, procalcitonin, human chorionic gonadotropin, toxoplasma immunoglobulin M, and toxoplasma immunoglobulin G was evaluated before and after biotin depletion using streptavidin particles.

Results.—All tested immunoassays, with the exception of toxoplasma immunoglobulin M and toxoplasma immunoglobulin G, suffered from significant biotin interference. The depletion protocol removed assay interference due to biotin and produced results that were close or identical to initial prespike measurements.

Conclusions.—Despite an increase in turnaround times, biotin adsorption is a feasible countermeasure for biotin interference in Elecsys immunoassays. Until test kits with an increased resistance to the interference from high-dose biotin intake are distributed, the evaluated protocol can provide results properly reflecting the patient’s clinical condition.

Laboratory analyses play a paramount role in about 70% of medical decisions and must be highly reliable to avoid false or missed diagnoses or unnecessary diagnostic procedures and treatments. Currently, around 85% of the most common immunochemical analyzers are equipped with assays using the interaction between streptavidin and biotin (vitamin H/B7; coenzyme R). The design offers advantages including signal amplification and increased sensitivity. Unfortunately, this system can be vulnerable to interference from endogenous high biotin concentrations, causing false low results in sandwich immunoassays and false high results in competitive immunoassays. The skewed results can lead to misdiagnoses including suspected endocrine and autoimmune disorders, missed infectious or neoplastic diseases, delayed pregnancy detection, suspected drug intoxications, and missed myocardial infarctions. In total, 163 of the available 265 assays (62%) across kits by Roche Elecsys (81 of 81), Ortho Vitros (29 of 43), Siemens Dimension (21 of 26), Siemens Centaur (18 of 67), and Beckmann Coulter Access/DXi (14 of 48) are potentially susceptible to biotin interference. The impact of interference is dose dependent and specific to each platform and assay. Assays on Abbott’s ARCHITECT i series are supposed to be unaffected up until biotin concentrations of $1.0 \times 10^6$ pg/mL.

Because the recommended daily intake of biotin (30–75 μg) does not influence current assays, biotin interference used to be an uncommon phenomenon that was mostly limited to biotin-dependent patients with rare inherited metabolic disorders receiving daily dosages between 10 and 200 mg. But in recent years, long-term biotin supplementation in doses of 300 mg per day (4000–10 000

Accepted for publication November 7, 2019.
Published online January 16, 2020.
From the Department of Laboratory Medicine, MDI Limbach Berlin GmbH, Berlin, Germany (Mrosewski, Switkowski, Urbank); and the Department of Toxicology, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany (Stauch).
The authors have no relevant financial interest in the products or companies described in this article.
Corresponding author: Ingo Mrosewski, MD, Department of Laboratory Medicine, MDI Limbach Berlin GmbH, Aroser Allee 84, 13407 Berlin, Germany (email: ingo.mrosewski@mvz-labor-berlin.de).
times the recommended daily intake) has been adopted as a promising therapeutic strategy in progressive multiple sclerosis and other demyelinating disorders.\textsuperscript{12–16} Additionally, supplementation with high-dose biotin could be beneficial in the treatment of dermatitis, diabetes mellitus, and depression.\textsuperscript{17–22} In pregnancy, supplementation of up to 300 µg biotin per day might be required, which should not interfere with current immunoassays.\textsuperscript{17,22} Biotin is also very popular as a self-medication to reduce hair loss or to improve the condition of skin and nails in supraphysiological doses of up to 30 mg daily, and supplements containing as much as 100 mg of biotin are available over-the-counter.\textsuperscript{3,5,23} Patients often do not report these supplements in their medical history, which represents one of the greatest challenges in dealing with biotin interference.\textsuperscript{3,5,7}

A study at the Mayo Clinic (Rochester, Minnesota) found that in 7.4% of patients presenting to the emergency department biotin was present at sufficient concentrations to cause interference in immunoassays using biotin-streptavidin technology.\textsuperscript{24} These facts and several instances of actual mismanagement of patients taking high doses of biotin have raised concern about the reliability of biotin-susceptible immunoassays such that the US Food and Drug Administration,\textsuperscript{25} the British ACB Scientific Committee,\textsuperscript{26} the German Federal Institute for Drugs and Medical Devices,\textsuperscript{27} and the European Medicines Agency\textsuperscript{28} have found it necessary to issue public warnings.

The purpose of this study was to simulate the worst-case scenario, running samples with the upper limits of biotin, for potentially time-critical analytes and evaluate the effectiveness of a biotin-depletion protocol using streptavidin particles.

METHODS

Biotin Stock Solution and Sample Spiking

A stock solution containing 53.6 × 10^6 pg/mL biotin was made using 99.9% biotin lyophilized powder (catalog number B4501-500MG, lot number SLB58478, Sigma-Aldrich Chemie GmbH, Schenldorf, Germany) and 0.9% sodium chloride (B. Braun Melsungen AG, Melsungen, Germany). The solution’s biotin concentration was confirmed via enzyme-linked immunosorbent assay (ELISA) measurements in triplicate (Biotin ELISA Kit, reference number K 8141, Immunodiagnostik AG, Bensheim, Germany). This test is a competitive enzyme-linked assay with an upper quantification limit of 1100 pg/mL. The lower quantification limit is 48 pg/mL (evaluation according to Clinical and Laboratory Standards Institute guideline EP-17-A2).\textsuperscript{41} Samples containing biotin levels above the upper quantification limit had to be (repeatedly) diluted and reassayed. After confirmation of the stock solution’s biotin concentration, it was thoroughly vortexed again and aliquoted. Aliquots were frozen at −20°C until needed. For preparation of the biotin stock solution, a biotin concentration of 1.126 × 10^6 pg/mL of 4 parts of streptavidin solution per 1 part serum should achieve (near) complete biotin depletion. However, a considerable safety margin seems prudent because of biological variability with a broad standard deviation.\textsuperscript{4} Therefore, 1 part spiked serum (eg, 250 µL) was incubated with 5 parts streptavidin solution (eg, 1250 µL), leaving a safety margin of approximately 0.509 × 10^6 pg/mL for excess biotin. After adsorption, the biotin concentrations were reanalyzed via ELISA (Figure 2).

Evaluation of Adsorption Times

Using the 10 spiked serum samples, the efficiency of biotin adsorption during 15, 30, and 60 minutes was evaluated using pooled streptavidin-coated magnetic microparticles contained in all Roche Elecsys reagent packs at a concentration of 0.72 mg/mL (reagent M, Roche Deutschland Holding GmbH, Mannheim, Germany) (Figure 1). The binding capacity of streptavidin for free biotin is 0.327 × 10^6 pg/mL. With a target concentration of 1.126 × 10^6 pg/mL, 4 parts of streptavidin particles per 1 part serum should achieve (near) complete biotin depletion. Therefore, 1 part spiked serum (eg, 250 µL) was incubated with 5 parts streptavidin solution (eg, 1250 µL), leaving a safety margin of approximately 0.509 × 10^6 pg/mL for excess biotin. After adsorption, the biotin concentrations were reanalyzed via ELISA (Figure 2).

Interference of Biotin in Immunoassays

The interference of high-dose biotin in the assays for thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), digoxin, tacrolimus, cyclosporine A, cortisol, C-peptide, insulin, N-terminal pro-B–type natriuretic peptide (NT-proBNP), troponin T high sensitive (hs), human immunodeficiency virus (HIV), procainobin, β human chorionic gonadotropin (β-HCG), toxoplasma immunoglobulin (Ig) M, and toxoplasma IgG (Table 1) was evaluated on e 801 modules of Roche’s cobas 8000 modular analyzer series using a total of 160 different de-identified routine samples (10 different samples per assay) with varying analyte concentrations from patients without known biotin supplementation. After initial measurement, the samples were spiked with biotin stock solution as described above and then measurements were repeated. Then, after the 15-minute adsorption protocol described above, the samples were analyzed again. One measurement was performed from each specimen before biotin spiking, after biotin spiking, and after biotin adsorption. Initial results were compared versus results after spiking and after adsorption. The dilution caused by the addition of biotin stock solution was factored into the results by multiplying the measured analyte concentrations after spiking and after adsorption by a factor.
A difference of 10% or more between the means was considered to be significant.

Statistical Analysis

GraphPad Prism 8 (GraphPad Software, San Diego, California) was used for statistical analysis and graphical depiction. For better comparability, all results within a given set were normalized as percentages versus the initial measurement, which was set to the default of 100%. Graphical depiction was done as means ± standard error of the mean. Statistical analysis was performed by 1-way analysis of variance with Bonferroni multiple comparison posttest for paired observations. A threshold of \( P < .05 \) was set for statistical significance.

RESULTS

Sample Spiking

The 10 serum samples spiked with biotin stock solution reached biotin concentrations between \( 1.019 \times 10^6 \) pg/mL and \( 1.272 \times 10^6 \) pg/mL. The mean was \( 1.123 \times 10^6 \) pg/mL (SD = \( 0.088 \times 10^6 \) pg/mL). As confirmed via ELISA, 0.9% sodium chloride contained no relevant concentration of biotin (<48 pg/mL).

Evaluation of Adsorption Times

All 3 adsorption regimes led to significantly depleted biotin concentrations within the 10 spiked samples. The 60-minute adsorption protocol proved to be the most effective, with a mean remaining biotin concentration of 33.47 ± 9.95 pg/mL. The 30-minute regime resulted in a mean biotin concentration of 103.1 ± 159.9 pg/mL and the 15-minute regime led to a mean biotin concentration of 91.5 ± 172.9 pg/mL (Figure 2).

Biotin Interference in Competitive Immunoassays

High-dose biotin led to false high results in the competitive immunoassays for cortisol, cyclosporine A, digoxin, tacrolimus, FT3, and FT4. The mean positive bias in spiked samples ranged from 15% (cortisol) to 71% (tacrolimus) and was overall independent of initial analyte concentrations within the samples. The 15-minute adsorption protocol returned all results to levels that were close or identical to the original prespike measurements. Cyclosporine A and

Table 1. Overview of Evaluated, Potentially Time-Critical Analytes on Roche’s cobas 8000 Modular Analyzer Series, Their Thresholds for Biotin Interference, and the Range of Analyte Concentrations in This Study

| Parameter | Interference Threshold, \( \times 10^3 \) pg/mL | Analyte Range | Unit | Assay Type | Reference No. | Lot No. |
|-----------|------------------------------------------|----------------|------|------------|---------------|---------|
| ß-HCG     | 80                                       | 13.7–2061 mU/mL | Sandwich | 07251025190 | 385896 |
| Cortisol II | 70                                     | 5–22 µg/dL | Competitive | 07027150190 | 353299 |
| C-peptide | 60                                      | 0.8–6.3 ng/mL | Sandwich | 07027168190 | 359510 |
| Cyclosporine A | 30                               | 45–234 ng/mL | Competitive | 07251246190 | 372163 |
| Digitoxin | 50                                      | 8.8–38.3 ng/mL | Competitive | 07270206190 | 361549 |
| FT3 III   | 70                                      | 1.8–5.7 pg/mL | Competitive | 0727362190 | 348359 |
| FT4 III   | 100                                     | 0.7–4.1 ng/dL | Competitive | 0796887190 | 380330 |
| HIV Duo   | 28                                      | 3.1–756 COI | Sandwich | 0729542190 | 385056 |
| Insulin   | 60                                      | 4.1–28 mU/L | Sandwich | 07027539190 | 378508 |
| NT-proBNP II | 30                              | 24–4611 ng/L | Sandwich | 07027664190 | 358699 |
| PCT       | 30                                      | 0.14–19.5 µg/L | Sandwich | 07301715200 | 358856 |
| Tacrolimus | 30                                    | 1.75–8.74 µg/L | Competitive | 07251254190 | 375033 |
| Toxoplasma IgM | 60                                | 1–5.3 COI | Sandwich | 07028024190 | 387690 |
| Toxoplasma IgG | 60                             | 154–516 IU/mL | Sandwich | 07028008190 | 363409 |
| Troponin T hs | 20                             | 59.6–8889 pg/mL | Sandwich | 07028075190 | 370695 |
| TSH       | 25                                      | 0.3–3.6 µU/mL | Sandwich | 07028091190 | 386646 |

Abbreviations: ß-HCG, ß human chorionic gonadotropin; COI, cutoff index; FT3, free triiodothyronine; FT4, free thyroxine; HIV, human immunodeficiency virus; hs, high sensitive; Ig, immunoglobulin; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin; TSH, thyroid-stimulating hormone.

SI conversion factor: To convert FT4 to picomoles per liter, multiply by 12.871.

* All assays are manufactured by Roche Deutschland Holding GmbH, Mannheim, Germany. All thresholds for biotin interference are stated as provided by Roche’s Elecsys method sheets.38
Figure 3. Biotin interference in competitive immunoassays for cortisol, cyclosporine A, digitoxin, tacrolimus, free triiodothyronine (FT3), and free thyroxine (FT4). Regardless of initial analyte concentration, biotin caused statistically significant (**P < .001) interference in the immunoassays for cortisol (A), cyclosporine A (B), digitoxin (C), tacrolimus (D), FT3 (E), and FT4 (F). The adsorption procedure produced no statistically significant discrepancy when compared with the original prespike measurements (A through F). n = 10 per analyte.
tacrolimus showed the worst recoveries following depletion treatment, with 91% and 92%, respectively (Figure 3, A through F). Means, standard deviations, coefficients of variation (CVs), and CIs are shown in Table 2.

### Biotin Interference in Sandwich Immunoassays

High-dose biotin led to false low results in the sandwich immunoassays for C-peptide, insulin, TSH, NT-proBNP, troponin T hs, HIV, procalcitonin, and B-HCG. The mean negative bias in spiked samples ranged from 13% (B-HCG) to 98% (TSH) and was largely independent of initial analyte concentrations within the samples. The NT-proBNP assay was a notable exception. In this assay, 3 samples of different concentrations showed more than 90% signal loss, and the rest suffered from an average signal loss of 59%, amounting to a total mean negative bias of 69%. The postspike measurement was reduced to 5.9 ng/L in the sample containing 72.6 ng/L NT-proBNP (signal loss of 92%), to 30.5 ng/L in the sample containing 1888 ng/L NT-proBNP (signal loss of 93%). The sandwich immunoassays for toxoplasma IgM and toxoplasma IgG were largely unaffected by biotin. Mean postspike and recovery measurements for toxoplasma IgM equaled 104% and 102%, respectively. For toxoplasma IgG, the mean postspike and recovery measurements were 101% and 96%. The 15-minute adsorption protocol returned all results to levels that were close or identical to the original preadsorption measurements. Some of the measurements after adsorption showed results that were statistically significantly different from the original preadsorption measurement. However, the difference in means was always less than 10% and deemed insignificant with one exception: in the assay for insulin, only 85% of the original relative concentration could be recovered (Figures 4, A through F, and 5, A through D). Means, standard deviations, CVs, and CIs can be found in Table 3.

### DISCUSSION

As demonstrated by our results, the interference caused by high-dose biotin can lead to dangerously false results in a wide variety of analytes in time-critical situations, thereby possibly resulting in misdiagnoses and the mistreatment of patients. The often-recommended discontinuation of biotin intake for up to 7 (in one case 15) days seems

---

**Abbreviations:** FT3, free triiodothyronine; FT4, free thyroxine.

SI conversion factor: To convert FT4 to picomoles per liter, multiply by 12.871.

---

**Table 2. Percentage Means, Standard Deviations, and Coefficients of Variation (CVs) Postspiking and After Biotin Depletion and 95% Confidence Intervals (CIs) Original Versus Biotin-Spiked and Original Versus 15-Minute Adsorption in Evaluated Competitive Immunoassays on Roche’s cobas 8000 Modular Analyzer Series**

| Assay       | Biotin-Spiked, % | 95% CI Original Versus Biotin-Spiked, % | After Depletion, % | 95% CI Original Versus 15-min Adsorption, % | Manufacturer-Supplied CV for Comparable Analyte Ranges, % (Value) |
|-------------|------------------|----------------------------------------|-------------------|--------------------------------------------|-------------------------------------------------|
| Cortisol II | 115 2.9 2.5      | 112.8–117.0                            | 99 1.4 1.4        | 98.2–100.2                                | 1.1–1.6 (1.15–28.6 μg/dL)                         |
| Cyclosporine A | 144 23.5 16.3   | 127.5–161.2                            | 91 5.1 5.6        | 87.1–94.4                                | 2.0–3.7 (36.2–213 ng/mL)                          |
| Digitoxin   | 151 8.4 5.6      | 145.2–157.2                            | 103 4.3 4.2       | 100.3–106.3                              | 1.8–2.6 (7.86–38.4 ng/mL)                         |
| FT3 III     | 121 2.8 2.3      | 118.5–122.6                            | 102 3.5 3.4       | 99.6–104.6                              | 2.1–7.6 (0.96–4.49 pg/mL)                         |
| FT4 III     | 146 18.1 12.4    | 132.6–158.5                            | 102 6.7 6.6       | 97.1–106.7                              | 1.5–2.4 (1.01–4.22 ng/dL)                         |
| Tacrolimus  | 171 23.9 14.0    | 154.0–188.3                            | 92 4.0 4.3        | 89.4–95.1                               | 2.2–3.6 (1.80–8.91 μg/L)                          |

---

**Depletion and 95% Confidence Intervals (CIs) Original Versus Biotin-Spiked and Original Versus 15-Minute Adsorption**

**Table 3. Means, Standard Deviations, CVs, and CIs can be found in Table 2.**
Figure 4. Biotin interference in sandwich immunoassays for C-peptide, insulin, thyroid-stimulating hormone (TSH), N-terminal pro-B-type natriuretic peptide (NT-proBNP), troponin T high sensitive (hs), and human immunodeficiency virus (HIV). Biotin caused statistically significant ($**$P<.001) interference in the immunoassays for C-peptide (A), insulin (B), TSH (C), NT-proBNP (D), troponin T hs (E), and HIV (F). The depletion protocol produced statistically significant discrepancies, when compared with the original prespike measurements, in the assays for C-peptide (A) ($*$P=.04), insulin (B) ($**$P<.001), TSH (C) ($**$P<.001), and troponin T hs ($**$P<.001). n=10 per analyte.
bodies, anti–thyroid peroxidase antibodies, TSH, FT3, and FT4. Another work group evaluated incubation times of 0, 15, 30, 45, and 60 minutes in cardiac troponin T hs in samples spiked with $1.3 \times 10^6$ pg/mL biotin and found no difference in the effectiveness of incubation times. However, these analytes comprise only a fraction of the ones in this study, and shorter incubation times should be evaluated for all concerned assays before they are applied to minimize the increase in turnaround times even further.

Schrapp et al described that the interference in troponin T hs is independent of initial troponin concentrations, an observation that we also made in most tested competitive and sandwich immunoassays, with the exception of NT-proBNP. Trambas et al, on the other hand, found the interference of biotin caused proportional changes in sandwich immunoassays regardless of initial analyte concentrations, whereas competitive immunoassays showed a particularly exaggerated positive bias in samples with low analyte concentrations. Additionally, Trambas et al reported almost 100% recovery of relative C-peptide concentration after adsorption. The discrepancy between these observations might be due to the difference in evaluated assays, because not all immunoassays are equally susceptible to biotin interference, even if the manufacturer-supplied thresholds for biotin interference are identical. Additionally, Trambas et al started their evaluation of biotin interference in several competitive immunoassays (eg, for testosterone, estradiol, and progesterone) at very low analyte concentrations, and sandwich immunoassays were not evaluated at the extreme lower range of quantification. This might have biased the results.

Figure 5. Biotin interference in sandwich immunoassays for procalcitonin (PCT), ß human chorionic gonadotropin (Beta-HCG), toxoplasma (Toxo) immunoglobulin (Ig) M, and Toxo IgG. Biotin caused statistically significant (***$P < .001$) interference in the immunoassays for PCT (A), Beta-HCG (B), and Toxo IgM (C). In Toxo IgG (D), no statistical significance was detected postspike. The depletion protocol produced statistically significant discrepancies, when compared with the original prespike measurements, in the assays for PCT (A) (***$P < .001$), Toxo IgM (C) ($P = .04$), and Toxo IgG (D) ($P = .03$).

$n = 10$ per analyte.
In our study, the assays for FT3, FT4, and cortisol showed considerably less positive bias than would have been expected according to the studies by Piketty et al and Trambas et al. At 1000 pg/mL biotin, they found a widely spread relative positive bias of 237% to 328% for FT3, 431% or more for FT4, and 153% to 212% for cortisol. However, it should be noted that these authors used different platforms: Roche cobas e 411 (Piketty et al) and Roche cobas e 602 (Trambas et al). Also, the FT4 III assay with increased resistance to biotin was introduced in 2018 and therefore could not have been used in these studies submitted for publication in 2016 and 2017. Differing reference and lot numbers as well as lower sample sizes further complicate direct comparability.

Some case studies also showed considerably less positive bias in FT3 and/or FT4 than would have been expected. In 2018, Ardabilygazir et al evaluated a patient taking 200 mg biotin daily for more than 10 months whose FT3 and FT4 showed relative positive biases of 40% and 129% when compared with the hormone assessment before the initiation of biotin supplementation. Information about the Roche platform used was not provided.

Al-Salameh et al observed relative positive biases of 73% and 258% for FT3 and FT4 in a patient taking 300 mg biotin daily when they compared the results on their Roche cobas e 170 with measurements obtained on the Siemens ADVIA Centaur in 2017. The biotin concentrations in the patients’ blood were not assessed in these case reports, there was no attempt of biotin adsorption, and no information about the assay lot and reference numbers was given.

The lack of information about assays used is common in many case studies, which mostly date back to the time before generation III of the FT4 assay was introduced. Often, the biotin concentration within the patients’ blood was not assessed and the authors did not use any adsorption protocol. The use of varying Roche platforms or the complete lack of information about Roche platforms used complicates direct comparisons further.

The biotin resistance in the assays for toxoplasma IgM and toxoplasma IgG was remarkable. The experiment for these analytes was repeated with a freshly thawed aliquot of biotin stock solution as well as other patient samples and came to the same result (data not shown).

Our observations in FT3, FT4, cortisol, toxoplasma IgM, and toxoplasma IgG might suggest that we did not reach the desired target concentration for biotin when spiking these samples. However we find that unlikely, because achievement of the biotin target concentration was confirmed via ELISA, aliquots of the same stock solution were used throughout the study, the results in different analytes (eg, TSH, troponin T hs) matched observations made by other investigators, and pipetting was always performed by the same person. This could suggest a higher-than-manufacturer-reported threshold for biotin interference in these assays. Several independent studies have already confirmed much higher-than-manufacturer-reported interference thresholds in other assays. To our knowledge, no other work group has evaluated biotin interference in Elecsys assays for toxoplasma IgM and toxoplasma IgG. Additional investigation will be required to further evaluate the results obtained for FT3, FT4, cortisol, toxoplasma IgM, and toxoplasma IgG.

Like all currently available countermeasures for biotin interference, the evaluated method has certain weaknesses. The adsorption caused an increase in the CVs and analytical imprecision in all tested assays, with the exception of cortisol, FT3, NT-proBNP, and procalcitonin, when compared with the manufacturer–supplied CVs in a comparable parameter range (Tables 2 and 3). Schrapp et al made the same observation in their evaluation of biotin depletion in the Elecsys assay for troponin T hs. The increased CVs should not be problematic in most analytes, with the exception of troponin T hs and HIV. The H0/H1 protocol in suspected myocardial infarction as suggested by the European Society of Cardiology should not be used when biotin depletion is performed. The H0/H3 protocol in suspected myocardial infarction was confirmed via ELISA, aliquots of the same stock solution were used throughout the study, the results in different analytes (eg, TSH, troponin T hs) matched observations made by other investigators, and pipetting was always performed by the same person. This could suggest a higher-than-manufacturer-reported interference threshold for biotin interference in these assays. Several independent studies have already confirmed much higher-than-manufacturer-reported interference thresholds in other assays. To our knowledge, no other work group has evaluated biotin interference in Elecsys assays for toxoplasma IgM and toxoplasma IgG. Additional investigation will be required to further evaluate the results obtained for FT3, FT4, cortisol, toxoplasma IgM, and toxoplasma IgG.

The observed increase in CV might partly be due to minimal dilution effects or matrix changes caused by

### Table 3. Percentage Means, Standard Deviations, and Coefficients of Variation (CVs) Postspiking and After Biotin Depletion and 95% Confidence Intervals (CIs) Original Versus Biotin-Spiked and Original Versus 15-Minute Adsorption in Evaluated Sandwich Immunoassays on Roche’s cobas 8000 Modular Analyzer Series

| Assay       | Biotin-Spiked, % | 95% CI Original Versus Biotin-Spiked, % | After Depletion, % | 95% CI Original Versus 15-min Adsorption, % | Manufacturer-Supplied CV for Comparable Analyte Ranges, % (Value) |
|-------------|-----------------|----------------------------------------|-------------------|---------------------------------------------|---------------------------------------------------------------|
| β-HCG       | 87              | 7.3                                    | 81.9–92.3         | 97                                          | 4.3                                                          | 94.1–100.3                                               |
| C-peptide   | 48              | 9.8                                    | 40.5–54.6         | 92                                          | 2.7                                                          | 90.4–94.2                                               |
| HIV Duo     | 9               | 0.9                                    | 8.2–9.5           | 97                                          | 13.8                                                         | 87.4–107.2                                               |
| Insulin     | 39              | 4.6                                    | 35.8–42.4         | 85                                          | 6.0                                                          | 81.0–89.6                                               |
| NT-proBNP II| 31              | 17.0                                   | 19.2–43.5         | 94                                          | 3.3                                                          | 91.2–95.9                                               |
| PCT         | 11              | 3.1                                    | 8.4–12.9          | 92                                          | 3.3                                                          | 89.5–94.2                                               |
| Toxoplasma IgM| 104            | 1.7                                    | 102.3–104.7       | 102                                         | 1.4                                                          | 100.6–102.5                                             |
| Toxoplasma IgG| 101            | 2.8                                    | 98.5–102.6        | 96                                          | 3.5                                                          | 93.7–98.7                                               |
| Troponin T hs| 5              | 0.7                                    | 4.2–5.3           | 92                                          | 3.3                                                          | 89.8–94.6                                               |
| TSH         | 2               | 2.5                                    | 0.7–4.2           | 95                                          | 2.2                                                          | 93.5–96.6                                               |

Abbreviations: β-HCG, β human chorionic gonadotropin; COI, cutoff index; HIV, human immunodeficiency virus; hs, high sensitive; Ig, immunoglobulin; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin; TSH, thyroid-stimulating hormone.

* All calculated CVs are compared with manufacturer-supplied CVs for analyte ranges most closely matching the analyte ranges evaluated in this study as stated in Table 1. Because of the study design, the calculated CVs include the imprecision from the adsorption protocol and the analytical imprecision of the given assay.
residual preservative in the Eppendorf tubes during the incubation with reagent M. Leftover preservative can also distort free to total hormone equilibrium, and thus measured values. A further important source of possible error is inadequate immobilization of the streptavidin microparticles and contamination of the aspirated sample with streptavidin microparticles during pipetting. The biotin depletion procedure requires manual handling, care, and attentiveness, and can therefore be prone to human error. The experimental setup in this study resulted in prolonged air exposure in tacrolimus and cyclosporine A assays, which is cautioned against in Roche’s method sheets and might have resulted in a reduced recovery in these analytes. Because of the manual work steps, the depletion protocol cannot be applied indiscriminately to all samples. At the same time, a laboratory cannot determine the biotin concentration within all samples to screen out the ones needing pretreatment and still be expected to work in a time- and cost-efficient manner. Unfortunately, high–dose biotin supplements are also not traced via pharmacies in Germany and laboratories do not receive a list of patients who are taking biotin, unlike in France. Therefore, the successful implementation of the suggested countermeasure in selected samples is dependent on close communication with clinicians who must be aware of the interference caused by biotin and inform the laboratory of patients using biotin supplements (including time of last intake, dose, and duration). Ideally, that information should be provided to the laboratory before the samples are taken, so that the appropriate course of action with regard to the specific situation can be determined. We found an informative letter very helpful in this regard.

Our study relied on sample spiking using a biotin stock solution and cannot account for the interference caused by biotin metabolites, primarily bisnorbiotin and biotin sulfoxide, in vivo. However, the majority of biotin within plasma remains native biotin, of which more than 50% is secreted unchanged renally, and biotin metabolites are thought to affect immunoassays much less than native biotin. Also, our adsorption protocol would eliminate these metabolites at least partially from samples. Therefore, we feel confident that the obtained adsorption results are comparable with the situation in vivo. In fact, we have already succeeded in correcting biotin interference in thyroid function tests and thyroid antibody assays of 2 MS patients taking 300 mg biotin daily (R.S., M.U., and I.M., unpublished data, April 1, 2019).

Recently, Roche started the distribution of a new test kit for troponin T hs and TSH with a supposed resistance to biotin interference up to biotin concentrations of 1.2 × 10^6 pg/mL. Pending laboratory validation, this is an encouraging development for immunoassay reliability. It may take several years for Roche to complete the step-by-step replacement of further test kits. Until the new kits are delivered, the evaluated adsorption protocol will provide laboratories with a safe and easily implemented countermeasure for bias caused by biotin in their repertoire of solutions. When using adsorption protocols, successful biotin depletion should be confirmed by parallel analyzation of paired control samples, unspiked and spiked with a known concentration of biotin.

Alternatives to biotin depletion for the evaluation of discrepant assay results in non-time-critical situations include discontinuation of biotin supplementation and repeated analysis after biotin clearance, serial dilution of samples, and repeat testing on an alternate platform. As described above, each of these approaches suffers from specific drawbacks: serial dilutions can be time-consuming and overdilution can lead to inaccurate results, whereas repeat testing on an alternate platform usually requires sending samples to a reference laboratory for testing. Repeated analysis after biotin discontinuation and clearance might not be possible, because patients may not be available upon recognition of potential biotin interference. Regardless of the chosen evaluation method, direct measurement of biotin concentrations should be performed to confirm biotin as the likely cause of interference.

References
1. Ostronska M, Bartoszewicz Z, Bednarzuk T, Woclawek K, Zgliczyński W, Glinki P. The effect of biotin interference on the results of blood hormone assays. Endokrynol Pol. 2019;70(1):102–121.
2. Trambas C, Zhong L, Yen T, Sikaris K. Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Ann Clin Biochem. 2019;56(2):205–215.
3. Piketty ML, Prie D, Sedel F, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med. 2017;55(6):817–825.
4. Piketty ML, Acierno JS Jr, Switkowski R. Interference of high dose biotin supplementation with thyroid parameters in immunoassays utilizing the interaction between streptavidin and biotin: a case report and review of current literature. Clin Lab. 2019;65(1):165–168.
5. Civelli KY. Biotin interference in diagnostic tests. Clin Chem. 2017;63(2):619–620.
6. donti TR, Blackburn PR, Atwal PS. Holocarboxylase synthetase deficiency pre and post newborn screening. Mol Genet Metab Rep. 2016;7:40–44.
7. Navarro PC, Guerra A, Alvarez JG, Ortiz F. Cutaneous and neurologic manifestations of biotind Sign. Ann Dermatol. 2009;19(5):363–365.
8. Leng WQ, Al-Yamani E, Acierno JS Jr, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. J Neurol. 2010;257(1):16–26.
9. Minkovska A, Lee MN, Dowlatshahi M, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep. 2016;2(4):370–373.
10. Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomized, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–1731.
11. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015;4(2):159–169.
12. McCarty MF, DiNicolantonio JJ. Neuroprotective potential of high-dose biotin. Med Hypotheses. 2017;109:145–149.
13. Trambas CM, Sikaris KA, Liu XZ. More on biotin treatment mimicking Graves’ disease. N Engl J Med. 2016;375(17):1608–1608.
14. Mock DM. Biotin: from nutrition to therapeutics. Med Hypotheses. 2017;109:145–149.
15. Cameron P, Sikaris KA, Liu XZ. More on biotin treatment mimicking Graves disease. N Engl J Med. 2016;375(17):1608–1608.
16. Mock DM. Biotin: from nutrition to therapeutics. J Nutr. 2017;147(8):1487–1492.
17. Hemmati M, Balsa I, Abdolsaleheh M. Survey of the effect of biotin on glycemic control and plasma lipid concentrations in type 1 diabetic patients in Kermanshah in Iran (2008–2009). Oman Med J. 2011;26(3):195–198.
18. Maebashi M, Makino Y, Fukutaka Y, et al. Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Biochem Nutr. 1993;14(3):211–218.
19. McCarty MF. Biotin. In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enzymes and thereby aiding glycemic control. Med Hypotheses. 2016;95:43–48.
20. Dabushamurthi K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). Can J Physiol Pharmacol. 2015;93(5):355–362.
21. Mock DM. Adequate intake of biotin in pregnancy: why bother? J Nutr. 2014;144(12):1885–1886.
23. Holmes EW, Samarasinghe S, Emanuele MA, Meah F. Biotin interference in clinical immunoassays: a cause for concern. Arch Pathol Lab Med. 2017;141(11):1459–1460.

24. Katzman BM, Lueke AJ, Donato LJ, Jaife AS, Baumann NA. Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clin Biochem. 2018;60:11–16.

25. US Food and Drug Administration. The FDA warns that biotin may interfere with lab tests: FDA safety communication. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm586505.htm. Published November 28, 2017. Accessed September 17, 2019.

26. Association for Clinical Biochemistry & Laboratory Medicine. A statement from the ACB Scientific Committee regarding biotin / vitamin B7 interference in immunoassays issued July 2018. http://www.acb.org.uk/docs/default-source/documents/statement-from-acb-scicom-biotin-oct2018-1. Accessed July 20, 2019.

27. Bundesinstitut für Arzneimittel und Medizinprodukte [Federal Institute for Drugs and Medical Devices]. Rote-Hand-Brief zu biotinhaltigen Arzneimitteln: Risiko falscher Ergebnisse von Laboruntersuchungen durch Biotininterferenzen. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2019/rhb-biotin.html. Published May 15, 2019. Accessed July 20, 2019.

28. European Medicines Agency. PRAC recommendations on signals. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-14-17-january-2019-prac-meeting_en.pdf. Published February 2019. Accessed September 17, 2019.

29. Pohler A, Faigle J, Staack RF. Evaluation of potential biotin interference in immunogenicity testing [published online May 9, 2019]. Bioanalysis. 2019;11(17):1547–1554. doi:10.4155/bio-2019-0080

30. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol. 2016;12(3):327–344.

31. Ross DS, Burch HB, Cooper DS, et al. 2016 Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1342–1421.

32. Trambas C, Lu Z, Yin T, Sikaris K. Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays. Ann Clin Biochem. 2018;55(2):216–226.

33. Schrapp A, Fraissinet F, Hervouet C, Girot H, Brunel V. Biotin and high-sensitivity cardiac troponin T assay. Biochem Med (Zagreb). 2016;28(3):030901.

34. Ardalihgazir A, Alsharjiamcholu S, Mir D, Sachmechi I. Effect of high-dose biotin on thyroid function tests: case report and literature review. Cureus. 2018;10(6):e2845. doi:10.7759/cureus.2845

35. Al-Salameh A, Bequemont L, Brailly-Tabard S, Aubourg P, Chanson P. A somewhat bizarre case of Graves disease due to vitamin treatment. J Endocr Soc. 2017;1(5):431–435.

36. Bowen R, Benavides R, Coloń-Franco JM, et al. Best practices in mitigating the risk of biotin interference with laboratory testing [published online August 29, 2019]. Clin Biochem. doi:10.1016/j.clinbiochem.2019.08.012

37. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.

38. Roche Diagnostics GmbH. Roche Elecsys method sheets. Mannheim, Germany: Roche Diagnostics GmbH; 2016–2019. https://pim-eservices.roche.com/elD_SF/de/en/KeywordSearch. Accessed July 11, 2019.

39. Roche Diagnostics GmbH. Elecsys Troponin T hs [method sheet]. Mannheim, Germany: Roche Diagnostics GmbH; 2019. https://pim-eservices.roche.com/elD_SF/de/de/Documents/GetDocument?documentId=7e25b6-2199-e911-60c-00215a9b3428. Accessed July 15, 2019.

40. Roche Diagnostics GmbH. Elecsys TSH [method sheet]. Mannheim, Germany: Roche Diagnostics GmbH; 2019. https://pim-eservices.roche.com/elD_SF/de/de/Documents/GetDocument?documentId=501126e8-860-911-6595-00215a9b3428. Accessed September 17, 2019.

41. Clinical and Laboratory Standards Institute. CLSI EP17 – Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline. 2nd ed. Wayne, PA: CLSI; 2012.